ArticleCancer cell international2026
The prognostic value and oncogenic functions of WDR12 and its validation in osteosarcoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) stands as the predominant malignant primary bone tumor. WDR12 plays a role in diverse biological processes. Nonetheless, the specific function of WDR12 in OS has not been clearly elucidated. Herein, we found that WDR12 is overexpressed and closely associated with poor prognosis of OS. A diagnostic nomogram based on WDR12 and clinical features of OS could effectively predict the overall survival rate of OS patients. Through functional enrichment analysis, multiple potential pathways related to WDR12 expression in tumorigenesis have been identified. Additionally, the expression level of WDR12 is correlated with the tumor immune microenvironment, immune therapy response, and drug treatment response in OS. Importantly, in vitro experiments demonstrated that downregulation of WDR12 significantly inhibited the proliferation and migration abilities of OS cells and in vivo experiments also confirmed that overexpression of WDR12 could promote tumor growth. Hence, WDR12 has the capacity to emerge as a novel prognostic biomarker and therapeutic target for OS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.